PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
|Articles|March 19, 2020
Next-Generation Biopharmaceutical Development Services
Author(s)Catalent Pharma Solutions
Catalent Biologics is a global leader in biopharmaceutical development services, bringing next-generation therapies to the market.
Catalent Biologics is a global leader in biopharmaceutical development services, bringing next-generation therapies to the market. Its recent acquisitions of Paragon Bioservices and MaSTherCell have expanded its service portfolio to include development and manufacturing of cell and gene therapies, alongside new biological entities, biosimilars, sterile injectables, and antibody-drug conjugates.
Catalent Pharma Solutions
14 Schoolhouse Road Somerset, NJ 08873, USA
solutions@ catalent.com
tel. +1.888.765.8846
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.